Octreotide-Resistant Acromegaly: Challenges and Solutions

References

• Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119(11):3189–3202. doi:10.1172/JCI39375
   PubMed Web of Science ®Google Scholar
• Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS One. 2013;8(4):e61523. doi:10.1371/journal.pone.0061523
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999;2(1):29–41. doi:10.1023/A:1009965803750
   PubMedGoogle Scholar
• Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355(24):2558–2573. doi:10.1056/NEJMra062453
   PubMed Web of Science ®Google Scholar
• Christofides EA. Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly. Patient Prefer Adherence. 2016;10:1217–1225. doi:10.2147/PPA.S102302
   PubMed Web of Science ®Google Scholar
• Gatto F, Trifiro G, Lapi F, et al. Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. Endocrine. 2018;61(3):533–541. doi:10.1007/s12020-018-1630-4
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary. 2011;14(3):284–294. doi:10.1007/s11102-011-0310-7
   PubMed Web of Science ®Google Scholar
• Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377–382.
   PubMed Web of Science ®Google Scholar
• Abreu A, Tovar AP, Castellanos R, et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 2016;19(4):448–457.
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89–95. doi:10.1530/EJE-08-0267
   PubMed Web of Science ®Google Scholar
• Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf). 2010;72(2):203–208. doi:10.1111/cen.2010.72.issue-2
   PubMed Web of Science ®Google Scholar
• Katznelson L, Laws ER Jr., Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951. doi:10.1210/jc.2014-2700
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011;32(2):247–271. doi:10.1210/er.2010-0002
   PubMed Web of Science ®Google Scholar
• Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–561. doi:10.1038/s41574-018-0058-5
   PubMed Web of Science ®Google Scholar
• McKeage K. Pasireotide in acromegaly: a review. Drugs. 2015;75(9):1039–1048. doi:10.1007/s40265-015-0413-y
   PubMed Web of Science ®Google Scholar
• Bacigaluppi S, Gatto F, Anania P, et al. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center. Endocrine. 2016;51(3):524–533. doi:10.1007/s12020-015-0619-5
   PubMed Web of Science ®Google Scholar
• Abu Dabrh AM, Asi N, Farah WH, et al. Radiotherapy versus radiosurgery in treating patients with acromegaly: a systematic review and meta-analysis. Endocr Pract. 2015;21(8):943–956. doi:10.4158/EP14574.OR
   PubMed Web of Science ®Google Scholar
• Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243–248. doi:10.1038/nrendo.2014.21
   PubMed Web of Science ®Google Scholar
• Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93(8):2957–2968. doi:10.1210/jc.2008-0027
   PubMed Web of Science ®Google Scholar
• Carmichael JD, Bonert VS, Nuno M, Ly D, Melmed S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014;99(5):1825–1833. doi:10.1210/jc.2013-3757
   PubMed Web of Science ®Google Scholar
• Babu H, Ortega A, Nuno M, et al. Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors. Neurosurgery. 2017;81(2):357–366. doi:10.1093/neuros/nyx020
   PubMed Web of Science ®Google Scholar
• Giustina A, Arnaldi G, Bogazzi F, et al. Pegvisomant in acromegaly: an update. J Endocrinol Invest. 2017;40(6):577–589. doi:10.1007/s40618-017-0614-1
   PubMed Web of Science ®Google Scholar
• Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf). 2007;67(1):65–70. doi:10.1111/cen.2007.67.issue-1
   PubMed Web of Science ®Google Scholar
• Arafat AM, Mohlig M, Weickert MO, et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab. 2008;93(4):1254–1262. doi:10.1210/jc.2007-2084
   PubMed Web of Science ®Google Scholar
• Clemmons DR. IGF-I assays: current assay methodologies and their limitations. Pituitary. 2007;10(2):121–128. doi:10.1007/s11102-007-0032-z
   PubMed Web of Science ®Google Scholar
• Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem. 2011;57(4):555–559. doi:10.1373/clinchem.2010.150631
   PubMed Web of Science ®Google Scholar
• Schilbach K, Strasburger CJ, Bidlingmaier M. Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary. 2017;20(1):33–45. doi:10.1007/s11102-017-0792-z
   PubMed Web of Science ®Google Scholar
• Paragliola RM, Corsello SM, Salvatori R. Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary. 2017;20(1):109–115. doi:10.1007/s11102-016-0768-4
   PubMed Web of Science ®Google Scholar
• Fleseriu M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary. 2011;14(2):184–193. doi:10.1007/s11102-010-0282-z
   PubMed Web of Science ®Google Scholar
• Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90(8):4465–4473. doi:10.1210/jc.2005-0260
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Biermasz NR, Pereira AM, Romijn JA. Therapeutic options in the management of acromegaly: focus on lanreotide Autogel. Biol Targets Ther. 2008;2(3):463–479.
   PubMedGoogle Scholar
• Chanson P, Borson-Chazot F, Kuhn JM, et al. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf). 2008;69(2):299–305. doi:10.1111/j.1365-2265.2008.03208.x
   PubMed Web of Science ®Google Scholar
• Tutuncu Y, Berker D, Isik S, et al. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary. 2012;15(3):398–404. doi:10.1007/s11102-011-0335-y
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary. 2010;13(1):60–67. doi:10.1007/s11102-009-0169-z
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012;7(5):e36411. doi:10.1371/journal.pone.0036411
   PubMed Web of Science ®Google Scholar
• Cuevas-Ramos D, Fleseriu M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol. 2014;52(3):R223–R240. doi:10.1530/JME-14-0011
   PubMed Web of Science ®Google Scholar
• Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66(6):859–868. doi:10.1111/cen.2007.66.issue-6
   PubMed Web of Science ®Google Scholar
• Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary. 2010;13(1):18–28. doi:10.1007/s11102-009-0191-1
   PubMed Web of Science ®Google Scholar
• Shimatsu A, Teramoto A, Hizuka N, Kitai K, Ramis J, Chihara K. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. Endocr J. 2013;60(5):651–663. doi:10.1507/endocrj.EJ12-0417
   PubMed Web of Science ®Google Scholar
• Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary. 2016;19(3):235–247. doi:10.1007/s11102-015-0684-z
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. 2017;20(1):100–108. doi:10.1007/s11102-017-0791-0
   PubMed Web of Science ®Google Scholar
• Gatto F, Campana C, Cocchiara F, et al. Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. Rev Endocr Metab Disord. 2019;20:365–381. doi:10.1007/s11154-019-09506-y
   PubMed Web of Science ®Google Scholar
• Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol. 2005;153(2):187–193. doi:10.1530/eje.1.01968
   PubMed Web of Science ®Google Scholar
• Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest. 2006;29(9):826–830. doi:10.1007/BF03347378
   PubMed Web of Science ®Google Scholar
• Gatto F, Biermasz NR, Feelders RA, et al. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. Eur J Endocrinol. 2016;174(5):651–662. doi:10.1530/EJE-15-0391
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Kasuki L, Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab. 2013;24(5):238–246. doi:10.1016/j.tem.2012.11.007
   PubMed Web of Science ®Google Scholar
• Gatto F, Feelders RA, van der Pas R, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2013;98(1):E66–E71. doi:10.1210/jc.2012-2609
   PubMed Web of Science ®Google Scholar
• Wildemberg LE, Neto LV, Costa DF, et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest. 2013;36(1):38–43. doi:10.3275/8305
   PubMed Web of Science ®Google Scholar
• Ferone D, de Herder WW, Pivonello R, et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab. 2008;93(4):1412–1417. doi:10.1210/jc.2007-1358
   PubMed Web of Science ®Google Scholar
• Obari A, Sano T, Ohyama K, et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol. 2008;19(2):82–91. doi:10.1007/s12022-008-9029-z
   PubMed Web of Science ®Google Scholar
• Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schofl C. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol. 2013;169(4):391–400. doi:10.1530/EJE-13-0134
   PubMed Web of Science ®Google Scholar
• Kato M, Inoshita N, Sugiyama T, et al. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J. 2012;59(3):221–228. doi:10.1507/endocrj.EJ11-0177
   PubMed Web of Science ®Google Scholar
• Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary. 2013;16(4):490–498. doi:10.1007/s11102-012-0445-1
   PubMed Web of Science ®Google Scholar
• Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf). 2012;76(1):96–102. doi:10.1111/cen.2011.76.issue-1
   PubMed Web of Science ®Google Scholar
• Heck A, Ringstad G, Fougner SL, et al. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf). 2012;77(1):72–78. doi:10.1111/j.1365-2265.2011.04286.x
   PubMed Web of Science ®Google Scholar
• Potorac I, Petrossians P, Daly AF, et al. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocr Relat Cancer. 2016;23(11):871–881. doi:10.1530/ERC-16-0356
   PubMed Web of Science ®Google Scholar
• Grant M, Alturaihi H, Jaquet P, Collier B, Kumar U. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol. 2008;22(10):2278–2292. doi:10.1210/me.2007-0334
   PubMedGoogle Scholar
• Taboada GF, Luque RM, Neto LV, et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol. 2008;158(3):295–303. doi:10.1530/EJE-07-0562
   PubMed Web of Science ®Google Scholar
• Duran-Prado M, Gahete MD, Martinez-Fuentes AJ, et al. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab. 2009;94(7):2634–2643. doi:10.1210/jc.2008-2564
   PubMed Web of Science ®Google Scholar
• Duran-Prado M, Saveanu A, Luque RM, et al. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab. 2010;95(5):2497–2502. doi:10.1210/jc.2009-2247
   PubMed Web of Science ®Google Scholar
• Gatto F, Hofland LJ. The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer. 2011;18(6):R233–R251. doi:10.1530/ERC-10-0334
   PubMed Web of Science ®Google Scholar
• Treppiedi D, Mangili F, Giardino E, et al. Cytoskeleton protein Filamin A is required for efficient somatostatin receptor type 2 internalization and recycling through Rab5 and Rab4 sorting endosomes in tumor somatotroph cells. Neuroendocrinology. 2019. doi:10.1159/000503791
   PubMed Web of Science ®Google Scholar
• Treppiedi D, Jobin ML, Peverelli E, et al. Single-molecule microscopy reveals dynamic FLNA interactions governing SSTR2 clustering and internalization. Endocrinology. 2018;159(8):2953–2965. doi:10.1210/en.2018-00368
   PubMed Web of Science ®Google Scholar
• Gatto F, Feelders R, van der Pas R, et al. beta-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly. Endocrinology. 2013;154(12):4715–4725. doi:10.1210/en.2013-1672
   PubMed Web of Science ®Google Scholar
• Peverelli E, Giardino E, Treppiedi D, et al. Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells. Endocrinology. 2014;155(8):2932–2941. doi:10.1210/en.2014-1063
   PubMed Web of Science ®Google Scholar
• Coelho MCA, Vasquez ML, Wildemberg LE, et al. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. Sci Rep. 2019;9(1):1122. doi:10.1038/s41598-018-37692-3
   PubMed Web of Science ®Google Scholar
• Coelho MCA, Vasquez ML, Wildemberg LE, et al. Molecular evidence and clinical importance of beta-arrestins expression in patients with acromegaly. J Cell Mol Med. 2018;22(4):2110–2116. doi:10.1111/jcmm.13427
   PubMed Web of Science ®Google Scholar
• Venegas-Moreno E, Flores-Martinez A, Dios E, et al. E-cadherin expression is associated with somatostatin analogue response in acromegaly. J Cell Mol Med. 2019;23(5):3088–3096. doi:10.1111/jcmm.13851
   PubMed Web of Science ®Google Scholar
• Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab. 2010;95(5):2334–2342. doi:10.1210/jc.2009-2197
   PubMed Web of Science ®Google Scholar
• Peverelli E, Mantovani G, Lania AG, Spada A. cAMP in the pituitary: an old messenger for multiple signals. J Mol Endocrinol. 2014;52(1):R67–R77. doi:10.1530/JME-13-0172
   PubMed Web of Science ®Google Scholar
• Barlier A, Gunz G, Zamora AJ, et al. Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab. 1998;83(5):1604–1610. doi:10.1210/jcem.83.5.4797
   PubMed Web of Science ®Google Scholar
• Chahal HS, Trivellin G, Leontiou CA, et al. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J Clin Endocrinol Metab. 2012;97(8):E1411–E1420. doi:10.1210/jc.2012-1111
   PubMed Web of Science ®Google Scholar
• Chahal HS, Chapple JP, Frohman LA, Grossman AB, Korbonits M. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab. 2010;21(7):419–427. doi:10.1016/j.tem.2010.02.007
   PubMed Web of Science ®Google Scholar
• Cazabat L, Bouligand J, Salenave S, et al. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab. 2012;97(4):E663–E670. doi:10.1210/jc.2011-2291
   PubMed Web of Science ®Google Scholar
• Kasuki L, Vieira Neto L, Wildemberg LE, et al. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer. 2012;19(3):L25–L29.
   PubMed Web of Science ®Google Scholar
• Astruc B, Marbach P, Bouterfa H, et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J Clin Pharmacol. 2005;45(7):836–844.
   PubMed Web of Science ®Google Scholar
• McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. 2003;63(22):2473–2499.
   PubMed Web of Science ®Google Scholar
• Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism. 1996;45(8 Suppl 1):67–71.
   PubMed Web of Science ®Google Scholar
• Gatto F, Barbieri F, Arvigo M, et al. Biological and biochemical basis of the differential efficacy of first and second generation somatostatin receptor ligands in neuroendocrine neoplasms. Int J Mol Sci. 2019;20(16):3940.
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol. 2007;157(5):579–587.
   PubMed Web of Science ®Google Scholar
• Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol. 2009;161(2):331–338.
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Cannavo S, et al. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J Clin Endocrinol Metab. 2017;102(7):2454–2464.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Pivonello R, Ferreri L, Priscitelli P, Colao A. Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am. 2015;44(1):89–97.
   PubMed Web of Science ®Google Scholar
• Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327–1335.
   PubMed Web of Science ®Google Scholar
• Kuhn E, Chanson P. Cabergoline in acromegaly. Pituitary. 2017;20(1):121–128.
   PubMed Web of Science ®Google Scholar
• Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286(1–2):69–74.
   PubMed Web of Science ®Google Scholar
• Poll F, Lehmann D, Illing S, et al. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol. 2010;24(2):436–446.
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–799.
   PubMed Web of Science ®Google Scholar
• Gatto F, Feelders RA, Franck SE, et al. In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas. J Clin Endocrinol Metab. 2017;102(6):2009–2018.
   PubMed Web of Science ®Google Scholar
• Hofland LJ, van der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004;89(4):1577–1585.
   PubMed Web of Science ®Google Scholar
• Ibanez-Costa A, Rivero-Cortes E, Vazquez-Borrego MC, et al. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. J Endocrinol. 2016;231(2):135–145.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, Phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–884.
   PubMed Web of Science ®Google Scholar
• Shimon I, Adnan Z, Gorshtein A, et al. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine. 2018;62(2):448–455.
   PubMed Web of Science ®Google Scholar
• Schmid HA, Brue T, Colao A, et al. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine. 2016;53(1):210–219.
   PubMed Web of Science ®Google Scholar
• Coopmans EC, Muhammad A, van der Lely AJ, Janssen J, Neggers S. How to position pasireotide LAR treatment in acromegaly. J Clin Endocrinol Metab. 2019;104(6):1978–1988.
   PubMed Web of Science ®Google Scholar
• Grottoli S, Maffei P, Bogazzi F, et al. ACROSTUDY: the Italian experience. Endocrine. 2015;48(1):334–341.
   PubMed Web of Science ®Google Scholar
• Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr Pract. 2015;21(3):264–274.
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012;97(5):1589–1597.
   PubMed Web of Science ®Google Scholar
• Buchfelder M, van der Lely AJ, Biller BMK, et al. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol. 2018;179(6):419–427.
   PubMed Web of Science ®Google Scholar
• Ragonese M, Grottoli S, Maffei P, et al. How to improve effectiveness of pegvisomant treatment in acromegalic patients. J Endocrinol Invest. 2018;41(5):575–581. doi:10.1007/s40618-017-0773-0
   PubMed Web of Science ®Google Scholar
• Sievers C, Baur DM, Schwanke A, et al. Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort. Pituitary. 2015;18(6):916–923. doi:10.1007/s11102-015-0673-2
   PubMed Web of Science ®Google Scholar
• Franck SE, Korevaar TIM, Petrossians P, et al. A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues. Eur J Endocrinol. 2017;176(4):421–431. doi:10.1530/EJE-16-0956
   PubMed Web of Science ®Google Scholar
• Feola T, Cozzolino A, Simonelli I, et al. Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab. 2019;104(7):2892–2902. doi:10.1210/jc.2018-02281
   PubMed Web of Science ®Google Scholar
• Neggers SJ, Franck SE, de Rooij FW, et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2014;99(10):3644–3652. doi:10.1210/jc.2014-2032
   PubMed Web of Science ®Google Scholar
• Neggers SJ, de Herder WW, Feelders RA, van der Lely AJ. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary. 2011;14(3):253–258.
   PubMed Web of Science ®Google Scholar
• Madsen M, Poulsen PL, Orskov H, Moller N, Jorgensen JO. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab. 2011;96(8):2405–2413. doi:10.1210/jc.2011-0654
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Bernabeu I, Cap J, et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol. 2011;164(3):325–333. doi:10.1530/EJE-10-0867
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Ezzat S, D’Souza GA, Layton G, Strasburger CJ. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf). 2009;71(4):549–557. doi:10.1111/cen.2009.71.issue-4
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab. 2007;92(12):4598–4601. doi:10.1210/jc.2007-1234
   PubMed Web of Science ®Google Scholar
• Bianchi A, Valentini F, Iuorio R, et al. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res. 2013;32:40. doi:10.1186/1756-9966-32-40
   PubMed Web of Science ®Google Scholar
• Higham CE, Atkinson AB, Aylwin S, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab. 2012;97(4):1187–1193. doi:10.1210/jc.2011-2603
   PubMed Web of Science ®Google Scholar
• Bernabeu I, Alvarez-Escola C, Paniagua AE, et al. Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary. 2013;16(1):101–108. doi:10.1007/s11102-012-0382-z
   PubMed Web of Science ®Google Scholar
• Muhammad A, van der Lely AJ, Delhanty PJD, et al. Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE Study). J Clin Endocrinol Metab. 2018;103(2):586–595. doi:10.1210/jc.2017-02017
   PubMed Web of Science ®Google Scholar
• Muhammad A, Coopmans EC, Delhanty PJD, et al. Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. Eur J Endocrinol. 2018;179(5):269–277. doi:10.1530/EJE-18-0353
   PubMed Web of Science ®Google Scholar
• Yamada S, Fukuhara N, Oyama K, Takeshita A, Takeuchi Y. Repeat transsphenoidal surgery for the treatment of remaining or recurring pituitary tumors in acromegaly. Neurosurgery. 2010;67(4):949–956. doi:10.1227/NEU.0b013e3181ec4379
   PubMed Web of Science ®Google Scholar
• Mathioudakis N, Salvatori R. Management options for persistent postoperative acromegaly. Neurosurg Clin N Am. 2012;23(4):621–638. doi:10.1016/j.nec.2012.06.005
   PubMed Web of Science ®Google Scholar
• Abe T, Ludecke DK. Recent results of secondary transnasal surgery for residual or recurring acromegaly. Neurosurgery. 1998;42(5):1013–1021; discussion 1021–1012. doi:10.1097/00006123-199805000-00036
   Web of Science ®Google Scholar
• Ludecke DK. Value of transcavernous surgery in the treatment of pituitary adenomas. Eur J Endocrinol. 1995;133(2):147–148. doi:10.1530/eje.0.1330147
   PubMed Web of Science ®Google Scholar
• Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol. 2005;152(3):379–387. doi:10.1530/eje.1.01863
   PubMed Web of Science ®Google Scholar
• Kurosaki M, Luedecke DK, Abe T. Effectiveness of secondary transnasal surgery in GH-secreting pituitary macroadenomas. Endocr J. 2003;50(5):635–642. doi:10.1507/endocrj.50.635
   PubMed Web of Science ®Google Scholar
• Wilson TJ, McKean EL, Barkan AL, Chandler WF, Sullivan SE. Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications. Pituitary. 2013;16(4):459–464. doi:10.1007/s11102-012-0457-x
   PubMed Web of Science ®Google Scholar
• Almeida JP, Ruiz-Trevino AS, Liang B, et al. Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature. J Neurosurg. 2018;129(2):404–416. doi:10.3171/2017.2.JNS162673
   PubMed Web of Science ®Google Scholar
• Long H, Beauregard H, Somma M, Comtois R, Serri O, Hardy J. Surgical outcome after repeated transsphenoidal surgery in acromegaly. J Neurosurg. 1996;85(2):239–247. doi:10.3171/jns.1996.85.2.0239
   PubMed Web of Science ®Google Scholar
• Del Porto LA, Liubinas SV, Kaye AH. Treatment of persistent and recurrent acromegaly. J Clin Neurosci. 2011;18(2):181–190. doi:10.1016/j.jocn.2010.10.003
   PubMed Web of Science ®Google Scholar
• Shih HA, Loeffler JS. Radiation therapy in acromegaly. Rev Endocr Metab Disord. 2008;9(1):59–65. doi:10.1007/s11154-007-9065-x
   PubMed Web of Science ®Google Scholar
• Kim EH, Oh MC, Chang JH, et al. Postoperative gamma knife radiosurgery for cavernous sinus-invading growth hormone-secreting pituitary adenomas. World Neurosurg. 2018;110:e534–e545. doi:10.1016/j.wneu.2017.11.043
   PubMed Web of Science ®Google Scholar
• Ding D, GU M, MR P, et al. Stereotactic radiosurgery for acromegaly: an international multicenter retrospective cohort study. Neurosurgery. 2019;84(3):717–725. doi:10.1093/neuros/nyy178
   PubMed Web of Science ®Google Scholar